Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
NCT03099304 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
Conditions Studied
Interventions
- DRUG Vehicle cream
- DRUG Ruxolitinib cream
Study Locations (20)
California
- THE VITILIGO & PIGMENTATION INSTITUE OF SOUTHERN CALIFORNIA, 5670 Wilshire Boulevard — Los Angeles
- DERMATOLOGY RESEARCH ASSOCIATES- LOS ANGELES, 8930 S Sepulveda Blvd — Los Angeles
- DERMATOLOGY SPECIALISTS, 3629 Vista Way — Oceanside
Arkansas
- BURKE PHARMACEUTICAL RESEARCH LLC, 3633 Central Ave — Hot Springs
- NORTHWEST AR CLINICAL TRIALS CENTER, PLLC/HULL DERMATOLOGY, PA, 500 S 52nd Street — Rogers
Indiana
- DAWES FRETZIN CLINICAL RESEARCH GROUP, 8103 Clearvista Parkway — Indianapolis
- DS RESEARCH, 2241 Green Valley Road — New Albany
Massachusetts
- Tufts Medical Center, 260 Tremont Street — Boston
- UNIVERSITY OF MASSACHUESETTS, 364 Plantation Street — Worcester
Alabama
- UNIVERSITY OF ALABAMA AT BIRMINGHAM (UAB), 1802 6th Ave S — Birmingham
Connecticut
- CLINICAL RESEARCH CENTER OF CT, 27 Hospital Avenue — Danbury
Florida
- LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC/ AMERIDERM RESEARCH, 725 W Granada Blvd — Ormond Beach
Georgia
- EMORY UNIVERSITY, 1525 Clifton Road — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2021-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099304
The ClinicalTrials.gov registry entry for NCT03099304 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 163 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 2 interventions — of which Vehicle cream is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03099304 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Arkansas, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03099304 about?
NCT03099304 is a clinical study titled "A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo". The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
What is the current status of trial NCT03099304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2017-06-07. Estimated completion is 2021-09-08.
What conditions does trial NCT03099304 study?
This clinical trial studies the following conditions: Vitiligo. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03099304?
The interventions under investigation include: Vehicle cream (DRUG), Ruxolitinib cream (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03099304?
This trial is sponsored by Incyte Corporation, which has 163 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03099304 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.